Review





Similar Products

akkermansia muciniphila atcc baa 835 871 1101 231 alk ralstonia syzygii r24 821 1062 242 apy cand  (ATCC)
99
ATCC akkermansia muciniphila atcc baa 835 871 1101 231 alk ralstonia syzygii r24 821 1062 242 apy cand
Akkermansia Muciniphila Atcc Baa 835 871 1101 231 Alk Ralstonia Syzygii R24 821 1062 242 Apy Cand, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/akkermansia muciniphila atcc baa 835 871 1101 231 alk ralstonia syzygii r24 821 1062 242 apy cand/product/ATCC
Average 99 stars, based on 1 article reviews
akkermansia muciniphila atcc baa 835 871 1101 231 alk ralstonia syzygii r24 821 1062 242 apy cand - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
rna bee  (AMS Biotechnology)
96
AMS Biotechnology rna bee
Rna Bee, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rna bee/product/AMS Biotechnology
Average 96 stars, based on 1 article reviews
rna bee - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier
a priori information size apis framework  (STATA Corporation)
99
STATA Corporation a priori information size apis framework
Trial sequential analysis of progression-free survival (A) and overall survival (B) of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Horizontal orange lines represent the null line. Heterogeneity-adjusted a priori information size <t>(APIS)</t> to demonstrate or reject 15% relative risk reduction (RRR) of mortality risk (with a two-sided alpha of 5% and a statistical power of 80%) is 1990 patients <t>for</t> <t>PFS</t> and OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
A Priori Information Size Apis Framework, supplied by STATA Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a priori information size apis framework/product/STATA Corporation
Average 99 stars, based on 1 article reviews
a priori information size apis framework - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
delsys api  (Delsys Inc)
94
Delsys Inc delsys api
Trial sequential analysis of progression-free survival (A) and overall survival (B) of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Horizontal orange lines represent the null line. Heterogeneity-adjusted a priori information size <t>(APIS)</t> to demonstrate or reject 15% relative risk reduction (RRR) of mortality risk (with a two-sided alpha of 5% and a statistical power of 80%) is 1990 patients <t>for</t> <t>PFS</t> and OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
Delsys Api, supplied by Delsys Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/delsys api/product/Delsys Inc
Average 94 stars, based on 1 article reviews
delsys api - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier
api 6500 q trap  (Danaher Inc)
99
Danaher Inc api 6500 q trap
Trial sequential analysis of progression-free survival (A) and overall survival (B) of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Horizontal orange lines represent the null line. Heterogeneity-adjusted a priori information size <t>(APIS)</t> to demonstrate or reject 15% relative risk reduction (RRR) of mortality risk (with a two-sided alpha of 5% and a statistical power of 80%) is 1990 patients <t>for</t> <t>PFS</t> and OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
Api 6500 Q Trap, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/api 6500 q trap/product/Danaher Inc
Average 99 stars, based on 1 article reviews
api 6500 q trap - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
apy  (Bruker Corporation)
99
Bruker Corporation apy
Trial sequential analysis of progression-free survival (A) and overall survival (B) of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Horizontal orange lines represent the null line. Heterogeneity-adjusted a priori information size <t>(APIS)</t> to demonstrate or reject 15% relative risk reduction (RRR) of mortality risk (with a two-sided alpha of 5% and a statistical power of 80%) is 1990 patients <t>for</t> <t>PFS</t> and OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
Apy, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apy/product/Bruker Corporation
Average 99 stars, based on 1 article reviews
apy - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
api content  (Shimadzu Corporation)
99
Shimadzu Corporation api content
Trial sequential analysis of progression-free survival (A) and overall survival (B) of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Horizontal orange lines represent the null line. Heterogeneity-adjusted a priori information size <t>(APIS)</t> to demonstrate or reject 15% relative risk reduction (RRR) of mortality risk (with a two-sided alpha of 5% and a statistical power of 80%) is 1990 patients <t>for</t> <t>PFS</t> and OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
Api Content, supplied by Shimadzu Corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/api content/product/Shimadzu Corporation
Average 99 stars, based on 1 article reviews
api content - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
api 4500 q trap triple quadrupole mass spectrometer  (Danaher Inc)
97
Danaher Inc api 4500 q trap triple quadrupole mass spectrometer
Trial sequential analysis of progression-free survival (A) and overall survival (B) of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Horizontal orange lines represent the null line. Heterogeneity-adjusted a priori information size <t>(APIS)</t> to demonstrate or reject 15% relative risk reduction (RRR) of mortality risk (with a two-sided alpha of 5% and a statistical power of 80%) is 1990 patients <t>for</t> <t>PFS</t> and OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
Api 4500 Q Trap Triple Quadrupole Mass Spectrometer, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/api 4500 q trap triple quadrupole mass spectrometer/product/Danaher Inc
Average 97 stars, based on 1 article reviews
api 4500 q trap triple quadrupole mass spectrometer - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier
scils lab api  (Bruker Corporation)
97
Bruker Corporation scils lab api
Trial sequential analysis of progression-free survival (A) and overall survival (B) of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Horizontal orange lines represent the null line. Heterogeneity-adjusted a priori information size <t>(APIS)</t> to demonstrate or reject 15% relative risk reduction (RRR) of mortality risk (with a two-sided alpha of 5% and a statistical power of 80%) is 1990 patients <t>for</t> <t>PFS</t> and OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
Scils Lab Api, supplied by Bruker Corporation, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/scils lab api/product/Bruker Corporation
Average 97 stars, based on 1 article reviews
scils lab api - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier
api 5500  (Danaher Inc)
98
Danaher Inc api 5500
Trial sequential analysis of progression-free survival (A) and overall survival (B) of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Horizontal orange lines represent the null line. Heterogeneity-adjusted a priori information size <t>(APIS)</t> to demonstrate or reject 15% relative risk reduction (RRR) of mortality risk (with a two-sided alpha of 5% and a statistical power of 80%) is 1990 patients <t>for</t> <t>PFS</t> and OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.
Api 5500, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/api 5500/product/Danaher Inc
Average 98 stars, based on 1 article reviews
api 5500 - by Bioz Stars, 2026-04
98/100 stars
  Buy from Supplier

Image Search Results


Trial sequential analysis of progression-free survival (A) and overall survival (B) of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Horizontal orange lines represent the null line. Heterogeneity-adjusted a priori information size (APIS) to demonstrate or reject 15% relative risk reduction (RRR) of mortality risk (with a two-sided alpha of 5% and a statistical power of 80%) is 1990 patients for PFS and OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.

Journal: Frontiers in Immunology

Article Title: Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis

doi: 10.3389/fimmu.2026.1780791

Figure Lengend Snippet: Trial sequential analysis of progression-free survival (A) and overall survival (B) of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer. Red inward-sloping line to the left represents trial sequential monitoring boundary. Blue line represents evolution of cumulative Z-score. Horizontal green lines represent the conventional boundaries for statistical significance. Horizontal orange lines represent the null line. Heterogeneity-adjusted a priori information size (APIS) to demonstrate or reject 15% relative risk reduction (RRR) of mortality risk (with a two-sided alpha of 5% and a statistical power of 80%) is 1990 patients for PFS and OS (vertical red line). Cumulative Z-curve crossing the trial sequential monitoring boundary or the APIS boundary provides firm evidence of effect.

Article Snippet: Time-to-event endpoints (PFS and OS) were evaluated using an a priori information size (APIS) framework implemented in Stata 12.0 and R 4.3.2, whereas dichotomous outcomes were assessed with TSA software v0.9.5.10 Beta to estimate the required information size (RIS) and to construct trial sequential monitoring boundaries.

Techniques: